Dietlein M - Search Results

1

Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.

Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Dietlein M, Wolf J, Kahraman D. Kobe C, et al. Among authors: dietlein m. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1117-27. doi: 10.1007/s00259-012-2118-8. Epub 2012 Apr 14. Eur J Nucl Med Mol Imaging. 2012. PMID: 22526960

2

Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.

Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Dietlein M, et al. Eur J Nucl Med. 1997 Nov;24(11):1342-8. doi: 10.1007/s002590050158. Eur J Nucl Med. 1997. PMID: 9371865 Clinical Trial.

3

Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?

Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Dietlein M, et al. Nuklearmedizin. 1998 Jan;37(1):12-7. Nuklearmedizin. 1998. PMID: 9467164

4

Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.

Dietlein M, Krug B, Groth W, Smolarz K, Scheidhauer K, Psaras T, Stützer H, Lackner K, Schicha H. Dietlein M, et al. Nucl Med Commun. 1999 Mar;20(3):255-61. doi: 10.1097/00006231-199903000-00008. Nucl Med Commun. 1999. PMID: 10093075 Clinical Trial.

5

Economic evaluation studies in nuclear medicine: the need for standardization.

Dietlein M, Knapp WH, Lauterbach KW, Schicha H. Dietlein M, et al. Eur J Nucl Med. 1999 Jun;26(6):663-80. doi: 10.1007/s002590050436. Eur J Nucl Med. 1999. PMID: 10369954 Review.

6

Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.

Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ. Grünwald F, et al. Among authors: dietlein m. Eur J Nucl Med. 1999 Dec;26(12):1547-52. doi: 10.1007/s002590050493. Eur J Nucl Med. 1999. PMID: 10638405

7

Iterative reconstruction: an improvement of technetium-99m MIBI SPET for the detection of parathyroid adenomas?

Moka D, Eschner W, Voth E, Dietlein M, Larena-Avellaneda A, Schicha H. Moka D, et al. Among authors: dietlein m. Eur J Nucl Med. 2000 May;27(5):485-9. doi: 10.1007/s002590050532. Eur J Nucl Med. 2000. PMID: 10853801 Clinical Trial.

8

Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.

Krug B, Dietlein M, Groth W, Stützer H, Psaras T, Gossmann A, Scheidhauer K, Schicha H, Lackner K. Krug B, et al. Among authors: dietlein m. Acta Radiol. 2000 Sep;41(5):446-52. doi: 10.1080/028418500127345668. Acta Radiol. 2000. PMID: 11016764

9

Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany.

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H. Dietlein M, et al. Eur J Nucl Med. 2000 Oct;27(10):1441-56. doi: 10.1007/s002590000324. Eur J Nucl Med. 2000. PMID: 11083532

10

Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.

Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, Schicha H. Dietlein M, et al. Eur J Nucl Med. 2000 Nov;27(11):1598-609. doi: 10.1007/s002590000376. Eur J Nucl Med. 2000. PMID: 11105815

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

272 results

Search Page